JP2001512664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001512664A5 JP2001512664A5 JP2000505277A JP2000505277A JP2001512664A5 JP 2001512664 A5 JP2001512664 A5 JP 2001512664A5 JP 2000505277 A JP2000505277 A JP 2000505277A JP 2000505277 A JP2000505277 A JP 2000505277A JP 2001512664 A5 JP2001512664 A5 JP 2001512664A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- compound
- cell
- activity
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 35
- 238000000034 method Methods 0.000 description 32
- 102000005962 receptors Human genes 0.000 description 31
- 108020003175 receptors Proteins 0.000 description 31
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 29
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 24
- 230000000694 effects Effects 0.000 description 18
- 239000000556 agonist Substances 0.000 description 13
- 210000004748 cultured cell Anatomy 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 108091006068 Gq proteins Proteins 0.000 description 11
- 102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 11
- 108091006065 Gs proteins Proteins 0.000 description 10
- 101100085138 Homo sapiens PTH1R gene Proteins 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940127126 plasminogen activator Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108010001789 Calcitonin Receptors Proteins 0.000 description 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 1
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 102000058004 human PTH Human genes 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/903,977 US6183974B1 (en) | 1997-07-31 | 1997-07-31 | Screening assays for G protein coupled receptor agonists and antagonists |
| US08/903,977 | 1997-07-31 | ||
| PCT/US1998/015877 WO1999006535A1 (en) | 1997-07-31 | 1998-07-30 | Screening assays for g protein coupled receptor agonists and antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001512664A JP2001512664A (ja) | 2001-08-28 |
| JP2001512664A5 true JP2001512664A5 (https=) | 2009-02-19 |
| JP4261766B2 JP4261766B2 (ja) | 2009-04-30 |
Family
ID=25418329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000505277A Expired - Lifetime JP4261766B2 (ja) | 1997-07-31 | 1998-07-30 | Ｇタンパク質結合レセプターアゴニストおよびアンタゴニストについてのスクリーニングアッセイ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6183974B1 (https=) |
| EP (1) | EP1012241B1 (https=) |
| JP (1) | JP4261766B2 (https=) |
| AT (1) | ATE291615T1 (https=) |
| AU (1) | AU8675098A (https=) |
| DE (1) | DE69829483T2 (https=) |
| ES (1) | ES2239398T3 (https=) |
| WO (1) | WO1999006535A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4486256B2 (ja) * | 1998-10-22 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体 |
| WO2001023521A2 (en) * | 1999-09-29 | 2001-04-05 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| AU2002339843B2 (en) * | 2001-07-23 | 2007-12-06 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (PTH) analogs |
| US7166463B2 (en) * | 2001-11-16 | 2007-01-23 | The Regents Of The University Of Colorado | Nucleic acids encoding modified olfactory cyclic nucleotide gated ion channels |
| US7795220B2 (en) * | 2003-03-19 | 2010-09-14 | The General Hospital Corporation | Conformationally constrained parathyroid hormones with alpha-helix stabilizers |
| JP4871128B2 (ja) * | 2003-07-17 | 2012-02-08 | ザ ジェネラル ホスピタル コーポレイション | 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| US7833730B2 (en) * | 2006-04-11 | 2010-11-16 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| WO2008019062A2 (en) * | 2006-08-04 | 2008-02-14 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| CN104072606B (zh) * | 2007-08-01 | 2017-09-22 | 总医院有限公司 | 利用g蛋白偶联受体和相关组合物的筛选方法 |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| MX358161B (es) | 2010-05-13 | 2018-08-06 | The General Hospital Corp Star | Analogos de hormona paratiroidea y usos para los mismos. |
| JP6093946B2 (ja) * | 2014-02-25 | 2017-03-15 | 国立大学法人東北大学 | Ｇタンパク質共役型受容体のシグナル伝達の検出方法 |
| US11975050B2 (en) | 2018-03-16 | 2024-05-07 | The General Hospital Corporation | Parathyroid hormone polypeptide conjugates and methods of their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5462856A (en) | 1990-07-19 | 1995-10-31 | Bunsen Rush Laboratories, Inc. | Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins |
| DE69233472T2 (de) * | 1991-04-05 | 2006-02-09 | The General Hospital Corp., Charlestown | Parathormonrezeptor und dafür codierende DNA |
| DE4138621A1 (de) | 1991-11-25 | 1993-06-17 | Boehringer Ingelheim Int | Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg |
-
1997
- 1997-07-31 US US08/903,977 patent/US6183974B1/en not_active Expired - Lifetime
-
1998
- 1998-07-30 EP EP98938160A patent/EP1012241B1/en not_active Expired - Lifetime
- 1998-07-30 DE DE69829483T patent/DE69829483T2/de not_active Expired - Lifetime
- 1998-07-30 ES ES98938160T patent/ES2239398T3/es not_active Expired - Lifetime
- 1998-07-30 JP JP2000505277A patent/JP4261766B2/ja not_active Expired - Lifetime
- 1998-07-30 AU AU86750/98A patent/AU8675098A/en not_active Abandoned
- 1998-07-30 AT AT98938160T patent/ATE291615T1/de not_active IP Right Cessation
- 1998-07-30 WO PCT/US1998/015877 patent/WO1999006535A1/en not_active Ceased
-
2000
- 2000-10-27 US US09/696,982 patent/US7033773B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001512664A5 (https=) | ||
| Wilson et al. | Role of the E1∧ E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31 | |
| Huang et al. | Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer | |
| Patel et al. | Cadherin switching in ovarian cancer progression | |
| BENS et al. | Corticosteroid-dependent sodium transport in a novel immortalized mouse collecting duct principal cell line | |
| Monteil et al. | Crimean–Congo haemorrhagic fever virus uses LDLR to bind and enter host cells | |
| Jing et al. | Degradation of Tyrosine Phosphatase PTPN3 (PTPH1) by Association with Oncogenic HumanPapillomavirus E6 Proteins | |
| Kakolyris et al. | Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref‐1) protein: A basis for its role in human disease | |
| Metzger et al. | Mammalian TAFII30 is required for cell cycle progression and specific cellular differentiation programmes | |
| Andresson et al. | Vacuolar H+-ATPase Mutants Transform Cells and Define a Binding Site for the Papillomavirus E5 Oncoprotein (∗) | |
| Matsuzono et al. | Functional domain mapping of peroxin Pex19p: interaction with Pex3p is essential for function and translocation | |
| Simonson et al. | Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential | |
| Tong et al. | Carboxypeptidase D is an avian hepatitis B virus receptor | |
| Bödding et al. | Ca2+ dependence of the Ca2+-selective TRPV6 channel | |
| Tomaic et al. | Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD | |
| Hucl et al. | High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor–dependent MCAT motif | |
| Hougaard et al. | Trafficking of human ADAM 12-L: retention in the trans-Golgi network | |
| Sato et al. | Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2 | |
| Zhang et al. | BLM helicase facilitates Mus81 endonuclease activity in human cells | |
| Castro et al. | Cornichon regulates transport and secretion of TGFα-related proteins in metazoan cells | |
| Kremlitzka et al. | Alternative translation and retrotranslocation of cytosolic C3 that detects cytoinvasive bacteria | |
| Allgood et al. | Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus-mediated procedure for high-efficiency DNA transfer | |
| Cong et al. | MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination | |
| Gu et al. | Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers | |
| Wang et al. | Pdc1 functions in the assembly of P bodies in Schizosaccharomyces pombe |